Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis among Nonvalvular Atrial Fibrillation Patients

Stroke

Volumn 47, Issue 6, 2016, Pages 1555-1561

  Shah, Anuj ^a   Shewale, Anand ^a   Hayes, Corey J ^a   Martin, Bradley C ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

anticoagulants; atrial fibrillation; cost effectiveness; quality adjusted life years; stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;

AGING; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DISEASE MODEL; DRUG COST; HYPERTENSION; NEW-ONSET ATRIAL FIBRILLATION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; UNITED STATES; AGED; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH INSURANCE; HUMAN; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK; SEVERITY OF ILLNESS INDEX; STROKE; THEORETICAL MODEL;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COST-BENEFIT ANALYSIS; DABIGATRAN; HUMANS; INSURANCE, HEALTH; MIDDLE AGED; MODELS, THEORETICAL; PYRAZOLES; PYRIDINES; PYRIDONES; QUALITY-ADJUSTED LIFE YEARS; RISK; RIVAROXABAN; SEVERITY OF ILLNESS INDEX; STROKE; THIAZOLES; WARFARIN;

EID: 84964227470     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.012325     Document Type: Article

References (45)

1. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142-1147. doi: 10.1016/j.amjcard.2013.05.063.
2. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973-977.
3. Ingall T. Stroke-incidence, mortality, morbidity and risk. J Insur Med. 2004;36:143-152.
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-e292. doi: 10.1161/01.cir.0000441139.02102.80.
5. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76. doi: 10.1016/j.jacc.2014.03.022.
6. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326-331. doi: 10.1038/clpt.2008.10.
7. Husten L. FDA approves new oral anticoagulant from Daiichi Sankyo. Forbes. January 8, 2015. http://www.forbes.com/sites/larryhusten/2015/01/08/fda-approves-new-oral-anticoagulant-from-daiichisankyo/. Accessed May 5, 2015.
8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104. doi: 10.1056/NEJMoa1310907.
9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891. doi: 10.1056/NEJMoa1009638.
10. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992. doi: 10.1056/NEJMoa1107039.
11. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561.
12. Krejczy M, Harenberg J, Marx S, Obermann K, Frölich L, Wehling M. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. J Thromb Thrombolysis. 2014;37:507-523. doi: 10.1007/s11239-013-0989-6.
13. Rognoni C, Marchetti M, Quaglini S, Liberato NL. Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a costeffectiveness analysis. J Thromb Thrombolysis. 2015;39:149-154. doi: 10.1007/s11239-014-1104-3.
14. Lee S, Anglade MW, Meng J, Hagstrom K, Kluger J, Coleman CI. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Circ Cardiovasc Qual Outcomes. 2012;5:472-479. doi: 10.1161/CIRCOUTCOMES.112.965251.
15. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Costeffectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110:845-851. doi: 10.1016/j. amjcard.2012.05.011.
16. Lee S, Mullin R, Blazawski J, Coleman CI. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One. 2012;7:e47473. doi: 10.1371/journal.pone.0047473.
17. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 2011;343:d6333.
18. Kamel H, Johnston SC, Easton JD, Kim AS. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2012;43:881-883. doi: 10.1161/STROKEAHA.111.641027.
19. Kamel H, Easton JD, Johnston SC, Kim AS. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology. 2012;79:1428-1434. doi: 10.1212/WNL.0b013e31826d5fe8.
20. Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105:908-919. doi: 10.1160/TH11-02-0089.
21. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1-11. doi: 10.7326/0003-4819-154-1-201101040-00289.
22. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562-2570. doi: 10.1161/CIRCULATIONAHA.110.985655.
23. You JH, Tsui KK, Wong RS, Cheng G. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS One. 2012;7:e39640. doi: 10.1371/journal.pone.0039640.
24. Mensch A, Stock S, Stollenwerk B, Müller D. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. Pharmacoeconomics. 2015;33:271-283. doi: 10.1007/s40273-014-0236-9.
25. Morais J, Aguiar C, McLeod E, Chatzitheofilou I, Fonseca Santos I, Pereira S. Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. Rev Port Cardiol. 2014;33:535-544. doi: 10.1016/j.repc.2014.02.020.
26. Kleintjens J, Li X, Simoens S, Thijs V, Goethals M, Rietzschel ER, et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics. 2013;31:909-918. doi: 10.1007/s40273-013-0087-9.
27. Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther. 2014;36:192-210.e20. doi: 10.1016/j.clinthera.2013.12.011.
28. Zheng Y, Sorensen SV, Gonschior AK, Noack H, Heinrich-Nols J, Sunderland T, et al. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Clin Ther. 2014;36:2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015.
29. Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. J Med Econ. 2014;17:587-598. doi: 10.3111/13696998.2014.923891.
30. Rognoni C, Marchetti M, Quaglini S, Liberato NL. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig. 2014;34:9-17. doi: 10.1007/s40261-013-0144-3.
31. Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Costeffectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44:1676-1681. doi: 10.1161/STROKEAHA.111.000402.
32. Wisløff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics. 2014;32:601-612. doi: 10.1007/s40273-014-0152-z.
33. Shewale A, Johnson J, Li C, Nelsen D, Martin B. Variation in anticoagulant recommendations by the guidelines and decision tools among patients with atrial fibrillation. Healthcare. 2015;3:130-145.
34. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, et al; ACC/AHA Task Force on Performance Measures; ACC/AHA Task Force on Practice Guidelines. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329-2345. doi: 10.1161/CIR.0000000000000042.
35. Forrester SH. Estimating the inpatient and outpatient costs of atrial fibrillation and associated adverse events. Value Heal. 2014;17:A109.
36. CPI detailed report data for August 2015. CPI medical care component inflation rates. Beureau of Labor Statistics Web site. http://www.bls.gov/cpi/cpid1508.pdf. Accessed December 3, 2015.
37. Pharmacy drug pricing. National Average Drug Acquisition Costs. Medicaid Web site. http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Pharmacy-Pricing. html. Accessed August 10, 2015.
38. Medicaid drug rebate program. Medicaid Web site. http://www.medicaid. gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program.html. Accessed May 10, 2015.
39. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-2692. doi: 10.1001/jama.290.20.2685.
40. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994;154:1449-1457.
41. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34:2060-2065. doi: 10.1161/01.STR.0000080678. 09344.8D.
42. Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost. 2010;104:1106-1115. doi: 10.1160/TH10-10-0642.
43. Janzic A, Kos M. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics. 2015;33:395-408. doi: 10.1007/s40273-014-0246-7.
44. Leibson CL, Hu T, Brown RD, Hass SL, O'Fallon WM, Whisnant JP. Utilization of acute care services in the year before and after first stroke: A population-based study. Neurology. 1996;46:861-869.
45. Holloway RG, Witter DM Jr, Lawton KB, Lipscomb J, Samsa G. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology. 1996;46:854-860.